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Abstract
Background: Pregnancy has been associated with a decreased risk of HIV disease progression in the highly active
antiretroviral therapy (HAART) era. The effect of timing of HAART initiation relative to pregnancy on maternal virologic,
immunologic and clinical outcomes has not been assessed.
Methods: We conducted a retrospective cohort study from 1997–2005 among 112 pregnant HIV-infected women who
started HAART before (N=12), during (N=70) or after pregnancy (N=30).
Results: Women initiating HAART before pregnancy had lower CD4+ nadir and higher baseline HIV-1 RNA. Women initiating
HAART after pregnancy were more likely to receive triple-nucleoside reverse transcriptase inhibitors. Multivariable analyses
adjusted for baseline CD4+ lymphocytes, baseline HIV-1 RNA, age, race, CD4+ lymphocyte count nadir, history of ADE, prior
use of non-HAART ART, type of HAART regimen, prior pregnancies, and date of HAART start. In these models, women
initiating HAART during pregnancy had better 6-month HIV-1 RNA and CD4+ changes than those initiating HAART after
pregnancy (20.35 vs. 0.10 log10 copies/mL, P=0.03 and 183.8 vs. 270.8 cells/mm
3, P=0.03, respectively) but similar to
those initiating HAART before pregnancy (20.32 log10 copies/mL, P=0.96 and 155.8 cells/mm
3, P=0.81, respectively). There
were 3 (25%) AIDS-defining events or deaths in women initiating HAART before pregnancy, 3 (4%) in those initiating HAART
during pregnancy, and 5 (17%) in those initiating after pregnancy (P=0.01). There were no statistical differences in rates of
HIV disease progression between groups.
Conclusions: HAART initiation during pregnancy was associated with better immunologic and virologic responses than
initiation after pregnancy.
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Introduction
Women comprise an increasing proportion of HIV-infected
persons, and most of these women are of child-bearing age [1].
Although mother-to-child transmission of HIV has been reduced
to ,2% of HIV-infected pregnancies due to universal prenatal
HIV counseling and testing, antiretroviral therapy, scheduled
Cesarean delivery, and avoidance of breastfeeding [2–4], chal-
lenges remain in improving primary prevention and antiretroviral
treatment of HIV-infected women. Moreover, the effects of these
interventions on maternal HIV disease progression have not been
fully assessed.
There are conflicting data in the literature on the effect of
pregnancy on HIV disease progression and survival among HIV-
infected women. Studies conducted early in the HIV epidemic
reported a possible association between pregnancy and accelerated
HIV disease progression [5–7], particularly in developing
countries [8,9]. However, studies conducted in the United States
and Europe did not find a detrimental effect of pregnancy [10–14].
These studies were conducted prior to the era of highly active
antiretroviral therapy (HAART) and had significant methodolog-
ical differences that made it difficult to asses the true effect of
pregnancy on HIV disease progression [15].
A study conducted by Tai et al of women from our HIV clinic
receiving care in the HAART era, found that pregnancy was
associated with a lower risk of HIV disease progression [16].
Although the pregnant women were younger and healthier at
HAART initiation than the women who did not become pregnant,
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deaths after controlling for age, baseline CD4+ lymphocytes and
HIV-1RNA, and durable virologic suppression. The findings
persisted after including a propensity score for pregnancy, and in
an analysis that matched pregnant and nonpregnant women
according to date of cohort entry, baseline CD4+ lymphocyte
count, receipt of HAART, and age at study entry. These results
suggested a possible beneficial interaction between pregnancy and
HAART in HIV-infected women.
However, to our knowledge, no study has examined the
response to HAART among HIV-infected women according to
timing of HAART initiation in relation to their pregnancy. We
hypothesized that women starting HAART during pregnancy
would have improved virologic, immunologic, and clinical
responses. If proven clinically significant, improved maternal
HIV outcomes would indicate the need to conduct similar studies
in resource-limited settings. We therefore conducted a retrospec-
tive cohort study to evaluate changes in HIV-1 RNA and CD4+
lymphocytes after starting HAART before, during, or after
pregnancy, and subsequent HIV disease progression while in care.
Materials and Methods
Study cohort
The study cohort was defined as HIV-1-infected women with at
least one pregnancy while receiving care (.1 visit) between 1
January 1997 and 31 December 2005 at the Comprehensive Care
Center (CCC) in Nashville, Tennessee. Only women who started
their first HAART regimen and had HIV-1 RNA and CD4+
lymphocyte measurements ,180 days prior to HAART initiation
were included in this study. This cohort was drawn from part of a
previously described cohort [16].
Clinical data were entered into an electronic medical record by
medical providers at the time of the patient encounter, by
automated data upload (e.g., laboratory results), or by clinic
personnel (e.g., deaths). Laboratory and antiretroviral therapy data
(including regimen and start and stop dates) were validated by
systematic chart review. The informed consent process was waived
in accordance with the Code of Federal Regulations (CFR) 45
CFR 46.116 (d). The study and the waiver of consent were
approved by the Vanderbilt Institutional Review Board.
Definition of study exposure
Study patients were classified according to timing of first
HAART initiation. Women were classified as initiating HAART
before, during, or after first pregnancy while in care if they started
first HAART $30 days before estimated date of conception
(DOC), ,30 days before DOC and #30 days after pregnancy
event (defined as delivery, miscarriage, or pregnancy termination),
or .30 days after pregnancy event, respectively. DOC was
determined by last menstrual period and/or fetal ultrasound. The
30-day window before date of conception was used due to
uncertainty of the estimated date of conception as determined by
last menstrual period [17–20]. The 30-day window after date of
pregnancy event was used because of continued changes in
immunologic parameters seen after pregnancy event that might
influence immunologic and virologic responses to HAART
[21,22]. Women who started HAART during pregnancy were
presumed to start HAART for prevention of mother-to-child HIV
transmission (PMTCT) and not for maternal health if they had no
previous opportunistic infections, had nadir CD4+ lymphocyte
count .350 cells/mm
3, and peak HIV RNA level any time prior
to HAART initiation while in care ,100,000 copies/mL [2].
HAART was defined as regimens of $7 days duration that
contained two nucleoside reverse-transcriptase inhibitors (NRTI)
plus a protease inhibitor (PI), a non-nucleoside reverse-transcrip-
tase inhibitor (NNRTI), or a third NRTI; one NRTI, one PI, plus
one NNRTI; 2 PIs plus one NNRTI or one NRTI; or any regimen
containing enfuvirtide. Non-HAART antiretroviral therapy (ART)
included mono- or dual-NRTI therapy.
Definition of study outcomes
Outcomes of interest were rates of HIV-1 RNA and CD4+
lymphocyte change during the first 180 days of HAART initiation
and HIV disease progression, which was defined as time to AIDS-
defining event (ADE) or death at any time after HAART
initiation. ADEs were based on the 1993 US Centers for Disease
Control and Prevention classification criteria [23], excluding
CD4+ lymphocytes ,200 cells/mm
3.
Study variables
Maternal characteristics such as age, race, baseline CD4+
lymphocyte count and percentage, CD4+ lymphocyte count nadir
(the lowest CD4+ lymphocyte count in care prior to pregnancy
event), baseline HIV-1 RNA, date of HAART start, hepatitis C
virus (HCV) serological status, hepatitis B virus (HBV) infection,
history of injection drug use (IDU) as an HIV acquisition risk
factor, history of ADE, prior use of non-HAART ART, date of
HAART start, and date of conception, and data on prior (i.e.,
prior to the study period) and subsequent (i.e., after the first
pregnancy while in care during the study period) pregnancies were
assessed.
Study period
Baseline (time 0) was defined as the date of initiation of first
HAART. For the analysis of HIV-1 RNA and CD4+ lymphocyte
responses to first HAART, the study period ended when one of the
following conditions were met: 1) 180 days after first HAART start
(to measure early changes in HIV-1 RNA and CD4+ lymphocyte
responses); 2) change in pregnancy status; 3) death; 4) 31
December 2005; 5) discontinuation of first HAART regimen; 6)
last clinic encounter date if before 31 December 2005. Change in
pregnancy status was defined as 30 days before DOC for women
initiating HAART before pregnancy and 30 days after pregnancy
event for women initiating HAART during pregnancy.
For the time to ADE or death analysis the study period ended
with the first ADE or death, last clinic encounter, or 31 December
2005. All events were reviewed and confirmed by study
investigators (PFR, GB, SPR).
Statistical analyses
STATA SE (version 9.2; Stata Corporation) was used for all
analyses. Continuous variables were compared with the Kruskal-
Wallis test. Categorical variables were compared with the Fisher’s
exact test.
HIV-1 RNA and CD4+ lymphocyte analyses
Linear mixed effects models [24] were used to calculate the rates
of HIV-1 RNA and CD4+ lymphocyte change according to timing
of first HAART initiation (before, during, or after pregnancy). We
fit models which adjusted for baseline CD4+ lymphocytes, baseline
HIV-1 RNA, age, race, CD4+ lymphocyte count nadir, history of
ADE, prior use of non-HAART ART, type of HAART regimen,
prior pregnancies, and date of HAART start. These variables were
chosen for inclusion in the analyses because of their clinical
significance. From these models, we derived the rates of HIV-1
Pregnancy and HAART
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between time and HAART initiation category (before, during, or
after pregnancy). We fit models that did not assume a linear
relationship between CD4+ lymphocytes, HIV-1 RNA and time
using restricted cubic splines. There was insufficient evidence to
suggest that these nonlinear models improved the fit of the data
(P.0.05 for all tests), so we report only the results of the linear
models.
We also performed secondary analyses of HIV-1 RNA and
CD4+ lymphocyte change including variables for HCV sero-status
and history of IDU on the subset of individuals for whom this
information was available. We examined the sensitivity of our
analyses by assuming that persons with missing HCV serological
status data and IDU data all had or did not have these conditions.
Due to the concern that differences in HIV-1 RNA detection
limits (400 and 50 copies/mL) during the study period could
explain the differences in HIV-1 RNA change between the groups,
we also performed sensitivity analyses assuming that every HIV-1
RNA value of ,400 copies/mL was equal to 399 copies/mL
instead of actual number of virions for HIV-1 RNA level between
50 and 399. Additional analyses of HIV-1 RNA and CD4+
lymphocyte changes repeated the above analyses excluding
women on triple-NRTI HAART regimens, since such regimens
are now not recommended despite their prior widespread use [25–
27]. Additionally, we repeated the above analyses after grouping
subjects based on DOC and date of pregnancy event without the
30-day window periods.
HIV disease progression analyses
Cox proportional hazards models compared rates of HIV
disease progression (ADE/death) according to timing of HAART
initiation, both unadjusted and adjusted for the propensity of
belonging to a particular HAART initiation category (before,
during, or after pregnancy). Propensity scores [28] for starting
first HAART before or after pregnancy versus during pregnancy
were derived from separate logistic regression models including
age, race, baseline CD4+ lymphocyte count and HIV-1 RNA
level, CD4+ lymphocyte count nadir, use of non-HAART ART,
type of HAART regimen, prior pregnancies, and date of
conception. We were unable to use history of IDU and history
of ADE because these variables perfectly predicted HAART
initiation groups.
We performed secondary analyses comparing rates of HIV
disease progression using HCV sero-status as an additional
covariate on the subset of individuals who had this information
available, and sensitivity analyses assuming that persons with
missing HCV sero-status data all had or did not have HCV
infection. We also repeated analyses excluding women on triple-
NRTI HAART regimens. Additionally, we repeated the above
analyses by grouping subjects based on DOC and date of
pregnancy event without the 30-day window periods.
Results
Patient characteristics
Of the 127 women who were pregnant and initiated their first
HAART while followed at the Comprehensive Care Center
during the study period, 112 had baseline HIV-1 RNA and CD4+
lymphocytes and were included in the HIV disease progression
analysis: 12 women started HAART before pregnancy, 70 women
started HAART during pregnancy, and 30 women started
HAART after pregnancy. Of the 112, 96 additionally had
follow-up labs available during the first 180 days after HAART
start and were included in the analysis of HIV-1 RNA and CD4+
lymphocytes following HAART initiation (Figure 1). Fifteen
women who did not meet inclusion criteria were similar to the
study subjects according to age, HAART duration, and proportion
with ADE or death. The 16 (of 112) women without follow-up labs
were similar to the study subjects according to age, baseline CD4+
lymphocytes, baseline HIV-1 RNA, HAART duration, and
proportion with ADE or death while in care.
Table 1 shows demographic and clinical characteristics of the
112 patients. The groups were similar according to age and race.
Women starting HAART before pregnancy had lower CD4+
lymphocyte count nadir, higher baseline HIV-1 RNA, higher
proportion with a history of ADE, started their first HAART at an
earlier date, were more likely to receive PI-based HAART, and
had a longer study period for ADE and death analyses, than
women who started HAART during or after pregnancy. Of those
with available data, rates of HCV infection and history of IDU
were similar across groups. A higher proportion of women who
started HAART after pregnancy received HAART regimens other
than PI- or NNRTI-based HAART (all were triple-NRTI-based
HAART regimens). They also were more likely to have received
non-HAART ART prior to HAART and conceived at an earlier
date compared to the other two groups. There were no cases of
HBV infection.
All women who initiated HAART before pregnancy presented
to the Comprehensive Care Center prior to the date of
conception, compared to 33% of women who initiated HAART
during or after pregnancy (P,0.001). Thirty (43%) women who
initiated HAART during pregnancy started HAART for PMTCT.
Of the 30 women, 19 (63%) stopped HAART within 90 days after
pregnancy event. Median (IQR) time between HAART initiation
and date of conception among 12 women who initiated before
pregnancy was 526 (364–1199) days. Median (IQR) time between
date of HAART initiation and pregnancy event among 70 women
who initiated HAART during pregnancy was 137 (109–169) days.
Among 30 women who initiated HAART after pregnancy,
median (IQR) time between a pregnancy event and HAART
initiation was 682 (364–1563) days. Finally, there were no cases of
mother-to-child transmission of HIV-1.
Among the 96 women included in the longitudinal analysis of
HIV-1 RNA and CD4+ lymphocytes following HAART start, the
study period (median (IQR)) was shorter for those initiating
HAART during pregnancy (135 (88–164) days) compared to
women initiating HAART before (180 (129–180) days) and after
pregnancy (180 (167–180) days) (P,0.001). The most common
reason for ending the study period was reaching 180 days of
follow-up for women who started HAART before and after
pregnancy and end of pregnancy for those who started HAART
during pregnancy.
Fifty-nine women initiating HAART during pregnancy had
more provider visits per month during the study period for HIV-1
RNA and CD4+ lymphocyte analysis (median 1.76 visits)
compared to 8 women initiating HAART before (median 0.58)
and 29 women initiating HAART after pregnancy (median 0.65)
(P,0.001). The median (range) number of HIV-1 RNA
measurements was 3 (2–4), 4 (2–9), and 3 (1–6) for those initiating
HAART before, during, or after pregnancy, respectively
(P,0.001). The median (range) number of CD4+ lymphocyte
measurements was 3 (2–3), 4 (2–4), and 2 (2–2) for the three groups
(P,0.001).
HIV-1 RNA following first HAART start
Figure 2 shows the unadjusted rate of HIV-1 RNA decline
during the study period for all women in each of the three groups.
After adjusting for baseline CD4+ lymphocytes, baseline HIV-1
Pregnancy and HAART
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prior use of non-HAART ART, type of HAART regimen, prior
pregnancies, and date of HAART start, estimated HIV-1 RNA
decline (95% confidence interval (CI)) over the 6 months after
HAART initiation for those initiating during pregnancy was
similar to that of women initiating prior to pregnancy (P=0.96)
but greater than that of women initiating after pregnancy
(P=0.03): 20.32 log10 copies/mL (95% CI21.45, 0.81), 20.35
log10 copies/mL (95% CI 20.57, 20.13), and 0.10 log10 copies/
mL (95% CI 20.46, 0.66) for women initiating HAART before,
during, or after pregnancy, respectively (Figure 3 and Table 2).
In secondary analyses that included persons in whom HCV
serological status and history of IDU data were available, the
difference in the estimated HIV-1 RNA decline between those
initiating HAART during and after pregnancy was no longer
statistically significant: 20.25 log10 copies/mL (95% CI 20.53,
0.03) for during and 0.09 log10 copies/mL (95% CI 20.57, 0.75)
for after (P=0.14). In all other secondary analyses described in the
Methods, the estimated HIV-1 RNA decline was greater for those
initiating HAART during pregnancy than after (P#0.03 for all
analyses, data not shown).
CD4+ lymphocyte count following first HAART start
Figure 4 shows the unadjusted rate of CD4+ lymphocyte
increase during the study period for all women in each of the three
groups. After adjusting for baseline CD4+ lymphocytes, baseline
HIV-1 RNA, age, race, CD4+ lymphocyte count nadir, history of
ADE, prior use of non-HAART ART, type of HAART regimen,
prior pregnancies, and date of HAART start, the estimated rate of
CD4+ lymphocyte increase over the 6 months after HAART
Figure 1. Flow chart for patient selection. HAART: Highly active antiretroviral therapy.
doi:10.1371/journal.pone.0006961.g001
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similar to that of women initiating before pregnancy (P=0.81) and
higher than that women initiating after pregnancy (P=0.03):
155.8 cells/mm
3 (95% CI 2107.6, 419.2), 183.8 cells/mm
3 (95%
CI 110.8, 256.9), and 270.8 cells/mm
3 (95% CI 2326.8, 185.3)
for those initiating HAART before, during, or after pregnancy
(Figure 3 and Table 2).
In all secondary analyses (described in Methods), the estimated
CD4+ lymphocyte rise was greater for those initiating HAART
during pregnancy than those initiating after pregnancy (P#0.04
for all analyses, data not shown).
HIV disease progression
A lower proportion of women progressed to ADE or death
among women starting first HAART during pregnancy compared
to those starting HAART before or after pregnancy: 3 (25%), 3
(4%), and 5 (17%) for women who started HAART before, during,
and after pregnancy, respectively (P=0.01). When women were
grouped based on DOC and date of pregnancy event without the
30-day window, the proportion of ADE/deaths did not change
between the groups (P=0.04). In Kaplan-Meier analysis using the
original definition of the groups, the differences in HIV disease
progression were not statistically significant (log-rank test, P=0.10)
(Figure 5). In multivariable Cox proportional hazards models that
included propensity scores for initiating HAART before or after
pregnancy (as described in the Methods), the hazard of ADE or
death did not statistically differ between the groups: compared to
those initiating HAART during pregnancy, the hazard ratio (HR)
was 1.56 (95% CI 0.17, 14.79; P=0.70) for initiating after
pregnancy and 0.14 (95% CI 0.01, 3.09; P=0.21) for initiating
prior to pregnancy.
Results were similar in secondary analyses that included HCV
sero-status in the propensity scores, analyses that excluded women
starting triple-NRTI-based regimens, and analyses which grouped
subjects based on DOC and date of pregnancy event without the
30-day window (data not shown).
Table 1. Demographic and clinical characteristics of the study population (N=112).
Characteristic
Started HAART before
pregnancy N=12
Started HAART during
pregnancy
* N=70
Started HAART after
pregnancy N=30 P
a
Age at first HAART start, median (IQR), years 26.5 (23.5–35) 25.5 (22–29) 26 (23–29.5) 0.42
Black race, no. (%) 5 (41.7) 36 (51.4) 12 (40.0) 0.56
Baseline CD4+ lymphocyte count, median (IQR), cells/mm
3 284 (50–472) 407 (306–494) 430 (144–515) 0.27
Baseline CD4+ lymphocyte percentage, median (IQR), percent 23 (10–34.5) 27 (21–33) 26 (14–34) 0.50
CD4+ lymphocyte count nadir, median (IQR), cells/mm
3 220 (37–414) 381 (272–465) 284 (130–416) 0.009
Baseline HIV-1 RNA level, median (IQR), log10 copies/mL 4.97 (4.20–5.17) 3.89 (3.37–4.49) 3.70 (2.97–4.58) 0.006
Prior ADE, no. (%) 3 (25.0) 1 (1.4) 1 (3.3) 0.01
HCV, no. (%) 2 (16.7) 4 (6.0) 5 (16.7) 0.14
Missing, no. (%) 0 3 (4.3) 0
IDU, no. (%) 1 (10.0) 3 (5.6) 5 (16.7) 0.24
Missing, no. (%) 2 (16.7) 16 (22.9) 0
HAART start date, median (IQR), month/year 07/1999 (08/1998–04/2000) 12/2001 (06/2000–01/2004) 04/2001 (08/1999–02/2003) 0.001
First HAART regimen 0.007
PI-based, no. (%) 7 (58.3) 23 (32.9) 7 (23.3)
NNRTI-based, no. (%) 3 (25.0) 31 (44.3) 6 (20.0)
Other, no. (%) 2 (16.7) 16 (22.9) 17 (56.6)
First HAART duration, median (IQR), months 24.1 (1.8–40.3) 6.7 (4.1–32.7) 11.2 (5.5–26.9) 0.76
Prior non-HAART ART use, no. (%) 4 (33.3) 20 (28.6) 26 (86.7) ,0.001
Used prior to pregnancy, no. (%) 4 (33.3) 20 (28.6) 10 (33.3)
Used during and/or after pregnancy, no. (%) – – 16 (53.3)
Date of conception, median (IQR), month/year 05/2001 (07/1999–12/2002) 07/2001 (01/2000–08/2003) 08/1998 (10/1997–09/1999) ,0.001
Pregnancy duration, median (IQR), weeks 37.5 (24–38) 38 (37–39) 38 (36–39) 0.05
Number of pregnancies prior to the study period, median (IQR) 1 (0–2.5) 1 (1–2) 2 (1–3) 0.26
Number of subsequent pregnancies during study period,
median (IQR)
0 (0–0.5) 0 0 (0–1) 0.13
Number of provider visits during study period/month,
median (IQR)
0.50 (0.37–0.54) 0.58 (0.35–0.95) 0.39 (0.34–0.62) 0.08
Study period duration for ADE and death analyses,
median (IQR), months
77.5 (60.1–83.1) 39.8 (17.8–57.4) 42.1 (15.0–67.0) 0.001
Note: HAART: highly active antiretroviral therapy. IQR: interquartile range. CD4+ lymphocyte count nadir: the lowest CD4+ lymphocyte count while in care. ADE: AIDS-
defining event. IDU: history of injection drug use as a risk factor for HIV infection acquisition. HCV: hepatitis C virologic status prior to first HAART initiation. NA: not
available. ART: antiretroviral therapy. PI: protease inhibitor. NNRTI: non-nucleoside reverse transcriptase inhibitor.
*The reference group.
aContinuous data were compared by Kruskal-Wallis test. Categorical data were compared by 2-sided Fisher’s exact test.
doi:10.1371/journal.pone.0006961.t001
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(solid black line) by timing of HAART initiation.
doi:10.1371/journal.pone.0006961.g002
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In this study, we compared 6-month changes in HIV-1 RNA
and CD4+ lymphocyte and long-term rates of ADE/death in
women starting first HAART before, during, or after pregnancy.
We found that HIV-1 RNA decline and CD4+ lymphocyte
increase were more rapid over the first 6 months among women
initiating HAART during pregnancy than after pregnancy.
However, there was insufficient evidence to conclude that the
rate of disease progression differed according to the timing of
HAART initiation relative to pregnancy. In a recent meta-analysis
[29], a 0.3 log10 increase in HIV-1 RNA was associated with a
Figure 3. Estimated rate of HIV-1 RNA and CD4+ lymphocyte change. The estimated rate of HIV-1 RNA decline and CD4+ lymphocyte increase
(small circles) and 95% confidence interval (vertical bars) by pregnancy group over the 6 months following HAART initiation, adjusted for baseline CD4+
lymphocyte count and HIV-1 RNA, age, race, CD4+ lymphocyte count nadir, prior ADE, prior use of non-HAART ART, HAART type, prior pregnancies, and
date of HAART start. Horizontal lines represent p-values in a pair-wise comparison (women who started HAART during pregnancy as a reference). Left
panel: The estimated rate of HIV-1 RNA decline: 20.32 log10 copies/mL (95% CI 21.45, 0.81) in women who started HAART before pregnancy, 20.35
log10 copies/mL (95% CI 20.57, 20.13) in women who started HAART during pregnancy, and 0.10 log10 copies/mL (95% CI 20.46, 0.66) in women who
started HAART after pregnancy. Right panel: The estimated rate of CD4+ lymphocyte increase: estimates were 155.8 cells/mm
3 (95% CI 2107.6, 419.2)
in women who started HAART before pregnancy, 183.8 cells/mm
3 (95% CI 110.8, 256.9) in women who started HAART during pregnancy, and
270.8 cells/mm
3 (95% CI 2326.8, 185.3) in women who started HAART after pregnancy.
doi:10.1371/journal.pone.0006961.g003
Table 2. Multivariable linear mixed effects models: independent predictors of HIV-1 RNA levels (log10 copies/mL) and CD4+
lymphocyte counts (cells/mm
3) during 6 months following first HAART initiation
*&.
Independent Variables
HIV-1 RNA level predictors,
Effect (95% CI) P
CD4+ lymphocyte count
predictors, Effect (95% CI) P
Change per month, women who started HAART during pregnancy 20.06 (20.09, 0.02) 0.002 30.6 (18.6, 42.9) ,0.001
Interaction term, women who started HAART before pregnancy
** 0.03 (21.03, 1.09) 0.96 228.1 (2258.5, 202.5) 0.81
Interaction term, women who started HAART after pregnancy
** 0.45 (0.5, 0.85) 0.03 2254.5 (2477.0, 232.2) 0.03
Baseline CD4+ lymphocyte count, per 100 cells/mm
3 increase 0.01 (20.12, 0.14) 0.86 50.6 (27.0, 74.2) ,0.001
CD4+ lymphocyte count nadir, per 100 cell/mm
3 increase 20.10 (20.24, 0.05) 0.25 72.5 (46.1, 99.0) ,0.001
Baseline HIV-1 RNA level, per log10 copies/mL increase 0.24 (0.06, 0.41) 0.01 20.36 (231.8, 31.08) 0.98
Age at first HAART start, per year 20.02 (20.04, 0.01) 0.25 3.8 (21.1, 8.8) 0.13
Black race 0.18 (20.09, 0.44) 0.19 27.9 (219.7, 75.5) 0.25
Prior ADE (yes/no) 0.58 (20.27, 1.43) 0.18 280.9 (2238.7, 76.9) 0.32
Prior non-HAART ART use (yes/no) 0.27 (20.07, 0.60) 0.16 40.8 (220.0, 101.5) 0.19
HAART type 0.01 (20.16, 0.18) 0.87 25.4 (236.9, 26.1) 0.74
Prior pregnancies (yes/no) 20.27 (20.59, 0.05) 0.10 246.1 (2104.6, 12.3) 0.12
Date of HAART initiation, per year 20.0004 (20.0006, 20.0002) ,0.001 20.004 (20.04, 0.03) 0.83
Note: 95% CI: 95% confidence interval. HAART: highly active antiretroviral therapy. CD4+ lymphocyte count nadir: the lowest CD4+ lymphocyte count while in care. ADE:
AIDS-defining event. Non-HAART ART: non-HAART antiretroviral therapy.
*Mixed effect model adjusted for baseline CD4+ lymphocyte count and HIV-1 RNA level, age, race, CD4+ lymphocyte count nadir, prior ADE, prior use of non-HAART
ART, HAART type, prior pregnancies, and date of HAART initiation.
&The reference group was women who started HAART during pregnancy.
**Interaction terms are equal to the difference in slopes of HIV-1 RNA and CD4+ lymphocyte changes between women who started HAART during pregnancy and those
who started HAART before or after pregnancy.
doi:10.1371/journal.pone.0006961.t002
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doi:10.1371/journal.pone.0006961.g004
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virologic response that we noted could potentially have clinical
significance. A study with a larger sample size and longer follow-
up is needed to assess for significant difference in clinical
outcomes.
The etiology of the improved virologic and immunologic
responses associated with HAART initiation during pregnancy is
likely multifactorial. The improved response could be due in part
to the differences among women in the three patient groups.
Women who started HAART after pregnancy were more likely to
have been previously exposed to non-HAART ART, to have
started triple-NRTI-based HAART regimens, and to have started
HAART during an earlier HAART era. These factors are known
to lead to poorer responses to HAART [25–27,30–32]. Addition-
ally, high proportion of women who started HAART during
pregnancy for presumed PMTCT rather than their own health.
However, the better virologic and immunologic responses in the
pregnant group persisted after adjusting for these factors in
multivariable models and after excluding persons on triple-NRTIs.
Second, improved health-related behavior during pregnancy, and
resumption of unhealthy behaviors postpartum [33,34] could
explain the better virologic and immunologic responses in this
group. Pregnancy also has been independently associated with
greater adherence to HAART [35–37]. Although we were unable
to directly assess for adherence, we measured the intensity of
clinical care via the number of provider visits per month. Women
initiating HAART during pregnancy were seen more frequently
during the study period. This in turn provided a better opportunity
to provide adherence counseling, which is a part of routine care of
pregnant women at the Comprehensive Care Center. Improved
adherence in turn could lead to virologic suppression [38,39],
prevention of ADE and death [40,41] and of mother-to-child
transmission [42]. The above factors may explain the poorer
virologic and immunologic responses to HAART in women
starting HAART after pregnancy. Third, the enhanced virologic
and immunologic response among women who started HAART
while pregnant could be related to the elevated levels of
progesterone and estrogen during pregnancy, which lead to an
increase in CD4+ CD25+ regulatory T cells and tolerance to
alloantigens such as fetal antigens [21,43]. Increased levels of
regulatory T cells might limit CD8+ lymphocyte effector function
that in turn could limit HIV-1 infection-associated immune
dysregulation and reduce immune cell exhaustion and pro-
grammed cell death [44,45]. Thus, the effect of pregnancy on
regulatory T cells could possibly lead to a better virologic response
to HAART among women starting first HAART during
pregnancy
Due to the observational nature of this study, we cannot make
causal inferences between timing of HAART initiation and HIV-
related outcomes. First, our study had low power to detect
differences in clinical outcomes between pregnancy groups. The
number of women who started HAART before pregnancy was
particularly low. Larger studies with longer follow-up may show
statistically significant differences in HIV disease progression.
Second, women have different indications for HAART initiation
during pregnancy [2] compared to the indications when women
Figure 5. Kaplan-Meier survival curve of progression to new AIDS-defining event or death by timing of HAART initiation. The
numbers of women at risk each year are also given.
doi:10.1371/journal.pone.0006961.g005
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baseline characteristics that are associated with immune recovery
and virologic suppression (such as baseline CD4+ lymphocyte
count and HIV-1 RNA, CD4+ lymphocyte count nadir [47],
injection drug use [48,49], and hepatitis C virus co-infection [50])
residual confounding by indication for HAART initiation might
still remain. Third, it should be recognized that of women who
started HAART prior to becoming pregnant only those who
survived were able to get pregnant at a later date and, therefore,
were included in our study. Fourth, we were unable to assess and
control for HIV-1 resistance that could be associated with prior
non-HAART ART exposure and may contribute to poorer
responses to HAART [51–56].
With the above noted, this study found an improved virologic
and immunologic response among women who started HAART
during pregnancy compared to women who started HAART after
pregnancy. Regardless of the underlying etiology, it is an
important finding that women initiating HAART during preg-
nancy had excellent virologic and immunologic responses; this
presumably benefits both the mother and the fetus. Larger studies
are warranted to assess for possible differences in subsequent HIV
disease progression, particularly in resource-limited settings, and to
investigate the factors associated with the improved outcomes
during pregnancy, such as adherence or underlying biologic
factors.
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